Law360, New York (August 16, 2011, 1:18 PM EDT) -- Abbott Laboratories on Friday continued its bid to protect the market for cholesterol drug Simcor, filing another patent infringement suit in Delaware against generic-drug maker Teva Pharmaceutical Industries Ltd.
Abbott and Abbott Respiratory LLC lodged the complaint over Teva's bid for U.S. Food and Drug Administration approval to market a generic Simcor, which contains niacin and simvastatin.
The plaintiff sued Teva in March and an additional three times in 2010 over Simcor. Friday's suit references Teva's bid for a green light to market tablets containing 500 milligrams of niacin extended release and 40 milligrams of simvastatin, while the previous complaints deal...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!